Table 1.
Base case incremental results for nivolumab compared with docetaxel
| aNSCLC histology | Incremental costs (¥ [US$a]) | Incremental LYs, undiscounted | Incremental LYs, discounted | Incremental QALYs | Incremental cost per LYG, undiscounted (¥ [US$a]) | Incremental cost per LYG, discounted (¥ [US$a]) | Incremental cost per QALY (¥ [US$a]) |
|---|---|---|---|---|---|---|---|
| Deterministic | |||||||
| Squamous | 214,353 (31,829) | 1.489 | 1.226 | 1.034 | 143,961 (21,376) | 174,821 (25,959) | 207,388 (30,794) |
| Non-squamous | 158,993 (23,608) | 1.228 | 0.995 | 0.833 | 129,477 (19,226) | 159,834 (23,733) | 190,919 (28,349) |
| Stochastic | |||||||
| Squamous | 245,149 (36,401) | – | – | 1.143 | – | – | 214,536 (31,856) |
| Non-squamous | 187,809 (27,887) | – | – | 0.854 | – | – | 219,971 (32,663) |
LYs were not included within the probabilistic sensitivity analyses
aNSCLC advanced non-small cell lung cancer, LY life-year, LYG life-year gained, QALY quality-adjusted life-year
aConversion using exchange rate ¥1 = US$0.148487; May 3, 2019; www.xe.com